Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

University Hospital, Strasbourg, France100 enrolled

Overview

At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Acromegaly

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Major subject (≥18 years old) * Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital * Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021 * In whom biological confirmation of recurrence has been demonstrated * Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes. Exclusion criteria: * Subject having expressed opposition to participating in the study * Treatment pre and / or post surgery by radiotherapy * No recurrence * No treatment with a somatostatin analogue for recurrence * Subject under guardianship, curatorship or safeguard of justice

Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts